Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: The Danish Breast Cancer Cooperative Group

Journal of Clinical Oncology

Volumn 26, Issue 9, 2008, Pages 1419-1426

  Kyndi, Marianne ^a   Sørensen, Flemming B ^a   Knudsen, Helle ^a   Overgaard, Marie ^a   Nielsen, Hanne Melgaard ^a   Overgaard, Jens ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HORMONE RECEPTOR; PROGESTERONE RECEPTOR; TUMOR MARKER;

ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; DENMARK; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MASTECTOMY; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; TISSUE MICROARRAY; TREATMENT RESPONSE; ADJUVANT THERAPY; ADULT; AGED; BREAST TUMOR; CANCER STAGING; CHEMISTRY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; KAPLAN MEIER METHOD; MIDDLE AGED; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PATHOLOGY; PREDICTION AND FORECASTING; RANDOMIZED CONTROLLED TRIAL; RISK; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; BREAST NEOPLASMS; DENMARK; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MASTECTOMY; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 41149125468     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.14.5565     Document Type: Article

References (55)

1. Bonadonna G, Brusamolino E, Valagussa P, et al: Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 294:405-410, 1976
2. Fisher B, Carbone P, Economou SG, et al: 1-Phenylalanine mustard (L-PAM) in the management of primary breast cancer: A report of early findings. N Engl J Med 292:117-122, 1975
3. Nissen-Meyer R, Kjellgren K, Malmio K, et al: Surgical adjuvant chemotherapy: Results with one short course with cyclophosphamide after mastectomy for breast cancer. Cancer 41:2088-2098, 1978
4. Overgaard M, Hansen PS, Overgaard J, et al: Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy: Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 337:949-955, 1997
5. Ragaz J, Jackson SM, Le N, et al: Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med 337:956-962, 1997
6. Overgaard M, Jensen MB, Overgaard J, et al: Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet 353:1641-1648, 1999
7. Eifel P, Axelson JA, Costa J, et al: National Institutes of Health Consensus Development Conference statement: Adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst 93:979-989, 2001
8. Goldhirsch A, Glick JH, Gelber RD, et al: Meeting highlights: International consensus panel on the treatment of primary breast cancer - Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol 19:3817-3827, 2001
9. Goldhirsch A, Glick JH, Gelber RD, et al: Meeting highlights: International expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 16:1569-1583, 2005
10. Goldhirsch A, Glick JH, Gelber RD, et al: Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. J Natl Cancer Inst 90:1601-1608, 1998
11. Goldhirsch A, Wood WC, Gelber RD, et al: Meeting highlights: Updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 21:3357-3365, 2003
12. Harris JR, Halpin-Murphy P, McNeese M, et al: Consensus Statement on postmastectomy radiation therapy. Int J Radiat Oncol Biol Phys 44:989-990, 1999
13. Kurtz J: The curative role of radiotherapy in the treatment of operable breast cancer. Eur J Cancer 38:1961-1974, 2002
14. Recht A, Edge SB, Solin LJ, et al: Postmastectomy radiotherapy: Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19:1539-1569, 2001
15. Truong PT, Olivotto IA, Whelan TJ, et al: Clinical practice guidelines for the care and treatment of breast cancer: 16. Locoregional postmastectomy radiotherapy. CMAJ 170:1263-1273, 2004
16. Clarke M, Collins R, Darby S, et al: Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials. Lancet 366:2087-2106, 2005
17. Overgaard M, Nielsen HM, Overgaard J: Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials. Radiother Oncol 82:247-253, 2007
18. Ragaz J, Olivotto IA, Spinelli JJ, et al: Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst 97:116-126, 2005
19. Nielsen HM, Overgaard M, Grau C, et al: Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: Long-term results from the Danish Breast Cancer Cooperative Group DBCG 82 b and c randomized studies. J Clin Oncol 24:2268-2275, 2006
20. Kyndi M, Sorensen FB, Knudsen H, et al: Tissue microarrays compared with whole sections and biochemical analyses: A subgroup analysis of DBCG82 b&c. Acta Oncol (in press)
21. Anderson WF, Chu KC, Chatterjee N, et al: Tumor variants by hormone receptor expression in white patients with node-negative breast cancer from the surveillance, epidemiology, and end results database. J Clin Oncol 19:18-27, 2001
22. Faneyte IF, Peterse JL, van Tinteren H, et al: Predicting early failure after adjuvant chemotherapy in high-risk breast cancer patients with extensive lymph node involvement. Clin Cancer Res 10:4457-4463, 2004
23. Nocito A, Kononen J, Kallioniemi OP, et al: Tissue microarrays (TMAs) for high-throughput molecular pathology research. Int J Cancer 94:1-5, 2001
24. Torhorst J, Bucher C, Kononen J, et al: Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol 159:2249-2256, 2001
25. Zhang D, Salto-Tellez M, Putti TC, et al: Reliability of tissue microarrays in detecting protein expression and gene amplification in breast cancer. Mod Pathol 16:79-84, 2003
26. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987
27. Slamon DJ, Godolphin W, Jones LA, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712, 1989
28. Owens MA, Horten BC, Da Silva MM: HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 5:63-69, 2004
29. Wolff AC, Hammond ME, Schwartz JN, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118-145, 2007
30. Yaziji H, Goldstein LC, Barry TS, et al: HER-2 testing in breast cancer using parallel tissue-based methods. JAMA 291:1972-1977, 2004
31. Pritchard KI, Shepherd LE, O'Malley FP, et al: HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 354:2103-2111, 2006
32. Carey LA, Perou CM, Livasy CA, et al: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295:2492-2502, 2006
33. Dent R, Trudeau M, Pritchard KI, et al: Triple-negative breast cancer: Clinical features and patterns of recurrence. Clin Cancer Res 13:4429-4434, 2007
34. Kim MJ, Ro JY, Ahn SH, et al: Clinicopathologic significance of the basal-like subtype of breast cancer: A comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum Pathol 37:1217-1226, 2006
35. Rodríguez-Pinilla SM, Sarrio D, Honrado E, et al: Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Clin Cancer Res 12:1533-1539, 2006
36. Sørlie T, Perou CM, Tibshirani R, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98:10869-10874, 2001
37. Haffty BG, Yang Q, Reiss M, et al: Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 24:5652-5657, 2006
38. Perou CM, Sorlie T, Eisen MB, et al: Molecular portraits of human breast tumours. Nature 406:747-752, 2000
39. Sorlie T, Tibshirani R, Parker J, et al: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100:8418-8423, 2003
40. Livasy CA, Karaca G, Nanda R, et al: Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 19:264-271, 2006
41. Pirollo KF, Tong YA, Villegas Z, et al: Onco. Radiat Res 135:234-243, 1993
42. Pietras RJ, Poen JC, Gallardo D, et al: Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res 59:1347-1355, 1999
43. Rozan S, Vincent-Salomon A, Zafrani B, et al: No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer. Int J Cancer 79:27-33, 1998
44. Stål O, Sullivan S, Wingren S, et al: C-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer. Eur J Cancer 31A:2185-2190, 1995
45. Hellman S: Karnofsky Memorial Lecture. Natural history of small breast cancers. J Clin Oncol 12:2229-2234, 1994
46. Tamoxifen for early breast cancer: An overview of the randomised trials - Early Breast Cancer Trialists' Collaborative Group. Lancet 351:1451-1467, 1998
47. Hutchins LF, Green SJ, Ravdin PM, et al: Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: Treatment results of Intergroup Protocol INT-0102. J Clin Oncol 23:8313-8321, 2005
48. Davidson NE: Ovarian ablation as adjuvant therapy for breast cancer. J Natl Cancer Inst Monogr 67-71, 2001
49. Cianfrocca M, Goldstein LJ: Prognostic and predictive factors in early-stage breast cancer. Oncologist 9:606-616, 2004
50. Ross JS, Fletcher JA: The HER-2/neu oncogene in breast cancer: Prognostic factor, predictive factor, and target for therapy. Oncologist 3:237-252, 1998
51. Ross JS, Fletcher JA, Linette GP, et al: The Her-2/neu gene and protein in breast cancer 2003: Biomarker and target of therapy. Oncologist 8:307-325, 2003
52. Hamilton A, Piccart M: The contribution of molecular markers to the prediction of response in the treatment of breast cancer: A review of the literature on HER-2, p53 and BCL-2. Ann Oncol 11:647-663, 2000
53. Knoop AS, Knudsen H, Balslev E, et al: Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol 23:7483-7490, 2005
54. Piccart MJ, Di Leo A, Hamilton A: HER2: A 'predictive factor' ready to use in the daily management of breast cancer patients? Eur J Cancer 36:1755-1761, 2000
55. Yamauchi H, Stearns V, Hayes DF: When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 19:2334-2356, 2001